Published in Int J Biol Markers on April 14, 2008
AlphaB-crystallin is found in detergent-resistant membrane microdomains and is secreted via exosomes from human retinal pigment epithelial cells. J Biol Chem (2010) 1.09
Bi-allelic CLPB mutations cause cataract, renal cysts, nephrocalcinosis and 3-methylglutaconic aciduria, a novel disorder of mitochondrial protein disaggregation. J Inherit Metab Dis (2015) 0.96
New focus on alpha-crystallins in retinal neurodegenerative diseases. Exp Eye Res (2010) 0.91
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
Expression of αB-crystallin and its potential anti-apoptotic role in oral verrucous carcinoma. Oncol Lett (2011) 0.78
Renal tumor with alpha b crystallin expression. Int J Clin Exp Pathol (2015) 0.75
HspB5 correlates with poor prognosis in colorectal cancer and prompts epithelial-mesenchymal transition through ERK signaling. PLoS One (2017) 0.75
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (2008) 4.38
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res (2001) 1.57
Biochemical analysis of the stress protein response in human oesophageal epithelium. Gut (1997) 1.50
Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J (1999) 1.47
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene (2012) 1.35
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene (1999) 1.30
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol (2005) 1.28
The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res (1996) 1.26
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer (2008) 1.21
Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene (2006) 1.18
Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene (2007) 1.17
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene (2012) 1.11
Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep (2009) 1.09
Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer (1997) 1.08
The immune response against Francisella tularensis live vaccine strain in Lps(n) and Lps(d) mice. FEMS Immunol Med Microbiol (1996) 1.07
The p53 knowledgebase: an integrated information resource for p53 research. Oncogene (2006) 1.07
Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J Biol Chem (2000) 1.05
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma (2010) 1.04
The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene (2010) 1.04
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci (2005) 1.01
Baculovirus recombinant expressing a secreted form of a transmembrane carcinoma-associated antigen. Cancer Res (1992) 1.01
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. Hum Mutat (2001) 0.99
Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene (1999) 0.99
DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer (1987) 0.97
HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene (1993) 0.96
On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philos Trans R Soc Lond B Biol Sci (1995) 0.96
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology (2012) 0.93
The immunomodulatory effect(s) of lead and cadmium on the cells of immune system in vitro. Toxicol In Vitro (2000) 0.92
A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer (1996) 0.91
Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer (1993) 0.90
Tumor suppressor protein p53 binds preferentially to supercoiled DNA. Oncogene (1997) 0.89
Francisella tularensis strain LVS resides in MHC II-positive autophagic vacuoles in macrophages. Folia Microbiol (Praha) (2007) 0.89
Proliferative activity in pancreatic intraepithelial neoplasias of chronic pancreatitis resection specimens: detection of a high-risk lesion. Neoplasma (2004) 0.88
Epitope analysis of the murine p53 tumour suppressor protein. Oncogene (1996) 0.86
Serum tissue polypeptide-specific antigen (TPS): what is its diagnostic value? Br J Cancer (2000) 0.85
p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene (1995) 0.84
Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol (1997) 0.83
Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell Mol Life Sci (2001) 0.83
The development and use of phospho-specific antibodies to study protein phosphorylation. Methods Mol Biol (2000) 0.83
Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer (1995) 0.83
[Solid pseudopapillary tumor of the pancreas: 5 case reports]. Rozhl Chir (2004) 0.82
Predicting local recurrence of carcinoma of the rectum after preoperative radiotherapy and surgery. Br J Surg (1989) 0.82
Subtypes of non-transformed human mammary epithelial cells cultured in vitro: histo-blood group antigen H type 2 defines basal cell-derived cells. Differentiation (1993) 0.82
Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J Immunother Emphasis Tumor Immunol (1994) 0.82
A panel of monoclonal antibodies to keratin no. 7: characterization and value in tumor diagnosis. Neoplasma (1990) 0.82
Second primary cancers - causes, incidence and the future. Klin Onkol (2014) 0.81
Protein quality control and cancerogenesis. Klin Onkol (2012) 0.81
Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay. J Immunol Methods (2000) 0.81
Differences in p53 and Bcl-2 expression in relation to cell proliferation during the development of human embryos. Mol Pathol (1998) 0.81
Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. Oncogene (2007) 0.81
Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol (1995) 0.81
Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1). Neoplasma (2004) 0.81
[Prognostic factors for cervical cancer]. Klin Onkol (2013) 0.80
[Ananlysis of phosphoproteins and signalling pathways by quantitative proteomics]. Klin Onkol (2014) 0.79
Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma (2009) 0.79
Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. Br J Cancer (1987) 0.79
DNA flow cytometry: a predictor of a high-risk group in cervical cancer. Cancer Detect Prev (1997) 0.79
Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733. Int J Cancer (1996) 0.79
[Chemosensitivity prediction in tumor cells ex vivo--difficulties and limitations of the method]. Klin Onkol (2008) 0.78
The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma. Neoplasma (1997) 0.78
Cloned antigens and antiidiotypes. Hybridoma (1995) 0.78
Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother (2000) 0.78
Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys (1994) 0.78
Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1. J Pathol (2000) 0.78
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. Neoplasma (2007) 0.78
Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer (1999) 0.78
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines. Mol Pathol (2002) 0.77
Anti-idiotype cancer vaccines: pre-clinical and clinical studies. In Vivo (1992) 0.77
Effects of Oxidation Agents and Metal Ions on Binding of p53 to Supercoiled DNA. J Biomol Struct Dyn (2000) 0.77
Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy. Physiol Res (1997) 0.77
[Sugars Interfere or Glycomics in the Field of Cancer Biomarkers]. Klin Onkol (2015) 0.76
Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study. Neoplasma (2015) 0.76
P63 - an important player in epidermal and tumour development. Klin Onkol (2012) 0.76
Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology (1993) 0.76
Differential expression of p73alpha in normal ectocervical epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma. Int J Gynecol Pathol (2003) 0.76
New monoclonal antibodies recognizing p53 protein phosphorylated by casein kinase II at serine 392. Folia Biol (Praha) (2001) 0.76
[Methods for studying tumor cell migration and invasiveness]. Klin Onkol (2014) 0.76
Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity. Br J Cancer (1998) 0.75
Increased breakage of chromosome 1 in lymphocytes of patients with testicular cancer after bleomycin treatment in vitro. Br J Cancer (1989) 0.75
TAp63gamma is required for the late stages of myogenesis. Cell Cycle (2015) 0.75
Pilot study of sole conformal peroperative interstitial brachyradiotherapy of early stage breast carcinoma using high-dose rate afterloading. Neoplasma (2005) 0.75
Monoclonal antibodies recognizing different epitopes of cytokeratin No.18. Folia Biol (Praha) (1989) 0.75
[HODIME life buoy?]. Rozhl Chir (2013) 0.75
Anti-idiotype vaccine in colorectal cancer patients. Hybridoma (1993) 0.75
[Importance of surgical pathology for oncosurgery]. Rozhl Chir (2014) 0.75
[Building Mass Spectrometry Spectral Libraries of Human Cancer Cell Lines]. Klin Onkol (2016) 0.75
[Diagnostic deficiencies of type I and II and their implications for cancer therapy]. Rozhl Chir (2013) 0.75
Our experience in the surgical treatment of liver tumors in the years 1994-1996. Wiad Lek (1997) 0.75
Histological grading and DNA content as predictors of distant metastases in squamous cell carcinoma of the uterine cervix. Arch Gynecol Obstet (1991) 0.75
Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy. Med Oncol (2006) 0.75
Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann N Y Acad Sci (2000) 0.75
Basin characteristics and nutrient losses: the EUROHARP catchment network perspective. J Environ Monit (2009) 0.75